Freedom of information (FOI) releases from MHRA

This is a disclosure log of Medicines and Healthcare products Regulatory Agency's responses to freedom of information (FOI) or environmental information regulations (EIR) requests that might be of wider public interest.

If you can't find the information you're looking for, you can make a new FOI request.

Filters

Clear filters

  • Keywords filters

  • Year filters

  • Month filters

2,267 disclosures

  1. Neulasta: FOI Request

    Please can you provide a copy of the current, approved Risk Management Plan for the following product: Product details: Neulasta 6 mg solution for injection Active substance: pegfilgrastim MA Number: PLGB 13832/0033 MAH: Amgen Ltd

    Published: 7 September 2026

  2. FOI Request – Borderline Advice ref 2026-000124

    Under the Freedom of Information Act 2000, I request a copy of the Borderline Advice response issued under reference 2026-000124.

    Published: 7 September 2026

  3. Inspection reports

    Many thanks for your response and for confirming the status of my request. I am grateful for your compromise for me to limit my request to five (5) PV inspection reports. After reviewing the line listing you provided, I would like to receive the following inspection reports: 1. Pfizer 2. MSD 3. Bayer 4. Organon 5. Advanz Pharma

    Published: 7 September 2026

  4. Clinical and Non-Clinical Overviews for PL PL 49578/0040

    Dear Sirs I am writing to request the clinical and non clinical overviews for PL PL 49578/0040 - Sucralfate 1 g/5 ml Oral Suspension by Roma Pharmaceuticals. Many thanks

    Published: 7 September 2026

  5. Inspection reports

    To reduce the burden of the request, I would like to amend it and proceed without the request for any follow-up correspondence relating to inspection outcomes. Please provide the inspection reports and any associated deficiency reports, CAPAs, or compliance letters only. Please let me know if any further refinement is required.

    Published: 7 September 2026

  6. FOI Request: Differin 0.1% w/w Gel 

    I am writing a Freedom of Information request in order to request authorisation details for the Differin 0.1% w/w Gel (PL 10590/0015). * Please can you confirm the legal basis and route of authorisation? * Please can you confirm the licencing history? * Please can you provide any available public assessment reports?

    Published: 7 September 2026

  7. Request a copy of Clinical overview- Co-codamol 15mg/500 mg tablets

    Can you please share Approved Clinical Overview for below product? Product name: Co-codamol 15 mg/500 mg tablets PL 44521/0001 MAH: Generic Speciality Pharma Limited

    Published: 7 September 2026

  8. Request for CHM Minutes Relating to RECOVERY Trial Hydroxychloroquine Review (May–June 2020)

    See attached

    Published: 7 September 2026

  9. Freedom of Information Request – MHRA Data Protection Officer

    Under the Freedom of Information Act 2000, please provide the name, job title and official contact details of the person currently acting as the MHRA’s Data Protection Officer. I look forward to receiving your response by 17 August 2026, in accordance with the statutory 20-working-day response period.

    Published: 7 September 2026

  10. FOI Time to evaluate drugs and treatments

    Under the FOI Act, please could you provide me with the average time it takes (in days) for the MHRA to evaluate new treatments and drugs for cancer patients? Please could you also share the target average (by days) that MHRA holds internally for evaluating new treatments and drugs for cancer patients? If possible, please cover the latest 12 month data available and any yearly comparisons that may be useful. If any parts of this request may fall under exemptions from freedom of information laws, please redact the smallest amount of information possible (not whole sentences or sections, as is the case here) and label each redacted part with the specific reason for exemption under the act. Please note that this redaction process should not be taken into account when accounting for the costs of carrying out the request. Please note the Information Commissioner's Office guidance that authorities should "Provide as much meaningful information as possible" and "As far as possible, ensure that what you provide makes sense. If you have redacted so much that the document is unreadable, consider what else you can do to make the information understandable and useful for the requester." https://ico.org.uk/for-organisations/foi/guide-to-managing-an-foi-request/responding-to-a-request/refusal-notice/

    Published: 7 September 2026